Supriya Lifescience IPO Review:

Supriya Lifescience Ltd. Initial Public offering (IPO) will open for subscription on December 16th, 2021, and close on December 20th, 2021. The company is looking to raise Rs. 700 crores through the IPO. Rs 200 Cr will be a fresh issue and the rest Rs 500 Cr will be Offer for Sale (OFS).

It is the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively. It is the largest exporter of Salbutamol Sulphate from India in Fiscal 2020.

In Fiscal 2021, the products of this company were exported to 78 countries and consumed by 1,060 customers including 286 distributors. The company has API business in Europe, Latin America, Asia, and North America.

Key competitors of the company

Divis Laboratory
Wanbury limited
Unichem Laboratories Ltd
Mangalam Drugs and Organics Limited,
IPCA Laboratories Limited
Teva API B.V

IPO Details

Purpose of the Issue
The net proceeds of the issue will be used for:

Funding capital expenditure requirements of the company
Repayment and/or pre-payment, in full or part, of certain borrowings availed by the company
General corporate purposes

In closing
In this article, we covered the Supriya Lifescience Limited IPO Review 2021. The Initial Public Offering opens on December 16th and closes on December 20th. For investors, it can be a good opportunity to look into the company and apply for the IPO after analysing the strengths and weaknesses of the company. Let us know what you think about the IPO in the comments below? Happy Investing!

Get The Latest Stock Updates, Equity Tips, Share Market Tips, Stock Market Tips, Intraday Tips @ Investelite Research

Leave a Reply

Your email address will not be published. Required fields are marked *